Chimeric guide rna integrating rna interference and crispr-cas13d and applications thereof

CN122357546APending Publication Date: 2026-07-10PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE) +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202610503978.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-16
Publication Date
2026-07-10

AI Technical Summary

Technical Problem

Existing RNA interference technologies are inefficient when targeting long non-coding RNAs located in the nucleus, and traditional RNAi platforms suffer from off-target effects and cytotoxicity. CRISPR-Cas13d technology has shortcomings in delivery and efficacy.

Method used

We designed a chimeric guide RNA (SS-Rx) composed of shRNA and crRNA, which combines with the stem-loop structure of Cas13d crRNA to achieve nuclear targeting and is processed into siRNA by Dicer. It is then integrated into Ago2 to form RISC and guides the cleavage of target mRNA.

Benefits of technology

It achieves efficient and specific silencing of target RNAs, including mRNA and lncRNA, significantly inhibits cancer-related genes, enhances gene silencing efficiency, and is suitable for various cell lines and multi-target applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122357546A_ABST
    Figure CN122357546A_ABST
Patent Text Reader

Abstract

This invention discloses a chimeric guide RNA integrating RNA interference and CRISPR-Cas13d and its applications. Utilizing the structural matching between shRNA and Cas13d crRNA, this invention embeds the complete Cas13d crRNA into the classic shRNA backbone, constructing a dual-pathway synergistic silencing chimeric guide RNA (SS-Rx). Experiments have demonstrated that SS-Rx possesses the dual activity of shRNA and CRISPR-Cas13d, exhibiting superior gene silencing efficiency compared to traditional RNA silencing tools, and can inhibit the proliferation, migration, and invasion of bladder cancer cells by suppressing tumor-related genes. This invention synergistically combines the advantages of RNA interference and CRISPR-Cas13d, providing an efficient and widely applicable framework for gene function research and RNA-targeted therapy, with significant economic benefits and broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Improvements in Machines for Making Card Tube Boxes.

    GB111499A